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Research
Most Americans have selenium intake rang-
ing from 60 to 220 µg/day (Combs 2001), 
well above the recommended dietary allow-
ance of 55 µg/day (Institute of Medicine and 
Panel on Dietary Antioxidants and Related 
Compounds 2000; Rayman 2008). This high 
level of intake, particularly compared with 
other countries, is attributable to the high 
soil content of selenium in several areas of 
the United States, which is eventually incor-
porated in the food chain (Rayman 2008). 
Although selenium is required for adequate 
function of glutathione peroxidase and other 
selenoproteins, the risk of selenium deficiency 
in the U.S. general population is negligible. 
Additional selenium intake at high intake 
levels does not increase glutathione peroxi-
dase synthesis or activity, but rather increases 
plasma selenium concentration by the non-
specific incorporation of selenomethionine 
into plasma proteins (Institute of Medicine 
and Panel on Dietary Antioxidants and 
Related Compounds 2000), with unknown 
health effects.
Bleys et al. (2007) reported a positive 
association between serum selenium con-
centrations and the prevalence of diabetes 
among participants in the Third National 
Health and Nutrition Examination Survey 
(NHANES III). Stranges et al. (2007) 
reported an increased risk of diabetes among 
participants randomized to long-term sele-
nium supplementation (200 µg/day) in the 
Nutritional Prevention of Cancer (NPC) 
trial. Recently, the Selenium and Vitamin 
E Cancer Prevention Trial (SELECT), a 
mega-trial aimed to evaluate the efficacy of 
selenium in preventing prostate cancer, was 
prematurely stopped by the data and safety 
monitoring committee because of lack of 
benefit on the primary end point and the 
possibility of an increased risk of diabetes in 
the selenium-only arm (Lippman et al. 2009). 
Additionally, high selenium status has been 
linked with hypercholesterolemia (Bleys et al. 
2008b) and hypertension (Laclaustra et al. 
2009) in the U.S. population.
Because there is a narrow range between 
selenium intake levels required for seleno-
protein synthesis and toxic levels (Institute of 
Medicine and Panel on Dietary Antioxidants 
and Related Compounds 2000), these find-
ings raise concerns of possible adverse cardio-
metabolic effects of high selenium exposure, 
at least in selenium-replete populations such 
as the United States. NHANES III and the 
NPC trial, however, were conducted dur-
ing the 1980s and early 1990s, and there are 
no recent data on the association of serum 
selenium levels with diabetes in the United 
States. The objective of this study was to 
evaluate the association of serum selenium 
concentrations with the prevalence of diabe-
tes using recently available NHANES data 
collected in 2003–2004. Moreover, we also 
evaluated the association between serum sele-
nium levels with fasting plasma glucose and 
glycosylated hemoglobin levels, biomarkers 
not previously considered.
Materials and Methods
NHANES is conducted by the National 
Center for Health Statistics (NCHS) using a 
complex multistage sampling design to obtain 
a probability sample of the civilian non-
institutionalized U.S. population. We used 
data from NHANES 2003–2004 (NCHS 
2003–2004), the most recent release with 
selenium data available in adults. Serum 
selenium measurements were restricted to 
participants ≥ 40 years of age (n = 3,299), 
of whom 1,302 participated in the morning 
examination and had a fasting blood sample. 
Among these, 1,273 participants had serum 
selenium measurements. To minimize the 
possibility of reverse causation in the associa-
tions examined, we excluded participants with 
self-reported coronary heart disease (n = 156), 
stroke (n = 80), or cancer (n = 173), leaving 
934 participants. We further excluded 16 par-
ticipants with missing body mass index (BMI) 
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Background: Increasing evidence suggests that high selenium levels are associated with diabetes 
and other cardiometabolic risk factors.
oBjectives: We evaluated the association of serum selenium concentrations with fasting plasma 
glucose, glycosylated hemoglobin levels, and diabetes in the most recently available representative 
sample of the U.S. population.
Methods: We used a cross-sectional analysis of 917 adults ≥ 40 years of age who had a fasting 
morning blood sample in the National Health and Nutrition Examination Survey 2003–2004. We 
evaluated the association of serum selenium, measured by inductively coupled plasma-dynamic reac-
tion cell-mass spectrometry, and diabetes, defined as a self-report of current use of hypoglycemic 
agents or insulin or as fasting plasma glucose ≥ 126 mg/dL.
results: Mean serum selenium was 137.1 µg/L. The multivariable adjusted odds ratio [95% con-
fidence interval (CI)] for diabetes comparing the highest quartile of serum selenium (≥ 147 µg/L) 
with the lowest (< 124 µg/L) was 7.64 (3.34–17.46). The corresponding average differences (95% 
CI) in fasting plasma glucose and glycosylated hemoglobin were 9.5 mg/dL (3.4–15.6 mg/dL) and 
0.30% (0.14–0.46%), respectively. In spline regression models, the prevalence of diabetes as well as 
glucose and glycosylated hemoglobin levels increased with increasing selenium concentrations up to 
160 µg/L.
conclusions: In U.S. adults, high serum selenium concentrations were associated with higher 
prevalence of diabetes and higher fasting plasma glucose and glycosylated hemoglobin levels. Given 
high selenium intake in the U.S. population, further research is needed to determine the role of 
excess selenium levels in the development or the progression of diabetes.
key words: diabetes, glycosylated hemoglobin, National Health and Nutrition Examination 
Survey, NHANES, selenium. Environ Health Perspect 117:1409–1413 (2009). doi:10.1289/
ehp.0900704 available via http://dx.doi.org/  [Online 15 May 2009]
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and 1 participant missing cotinine concentra-
tion. The final sample size was 917.
Serum selenium. Collection materials were 
screened for potential selenium contamina-
tion. Serum selenium was measured at the 
Trace Elements Laboratory at the Wadsworth 
Center of the New York State Department of 
Health (Albany, NY, USA) using inductively 
coupled plasma–dynamic reaction cell–mass 
spectrometry. The between-assay coefficients 
of variation for quality control pooled sam-
ples analyzed throughout the duration of the 
survey ranged from 2.5% to 2.9% (NCHS 
2003–2004).
Glucose, glycosylated hemoglobin, and dia-
betes. Plasma glucose was measured from a 
morning fasting sample of participants who 
fasted 8–24 hr by the enzyme hexokinase 
method (NCHS 2003–2004). Diabetes was 
defined as the presence of either a self-report 
of current use of hypoglycemic agents or insu-
lin or fasting plasma glucose ≥ 126 mg/dL. 
Similar associations between selenium and 
diabetes were found if the definition of diabe-
tes was based only on questionnaire or only on 
fasting plasma glucose levels (data not shown).
Glycosylated hemoglobin measurements 
were performed using the Primus CLC330 
and Primus CLC385 boronate affinity high-
performance liquid chromatography systems 
(Primus Corp., Kansas City, MO, USA). The 
systems were standardized to the reference 
method used for the Diabetes Control and 
Complications Trial (DCCT; 1993). The 
long-term interassay coefficient of variation 
was < 3.0% (NCHS 2003–2004).
Other variables. Information on sex, age, 
race/ethnicity, education, menopausal status, 
smoking, and use of vitamin/mineral supple-
ments (as a single yes/no question, including 
those supplements containing selenium) was 
based on self-report. BMI was calculated by 
dividing measured weight in kilograms by 
measured height in meters squared. Serum 
cotinine was measured by isotope-dilution 
high-performance liquid chromatography/
atmospheric pressure chemical ionization tan-
dem mass spectrometry (NCHS 2003–2004).
Statistical methods. Participants were 
divided into quartiles of serum selenium 
concentration based on the weighted popu-
lation distribution. We used multivariable 
linear regression to calculate adjusted means 
for plasma glucose and glycosylated hemo-
globin differences and logistic regression to 
calculate odds ratios (ORs) for diabetes com-
paring each quartile of serum selenium with 
the lowest quartile. We used three models with 
progressive degrees of adjustment. Model 1 
was adjusted for sex, age, race/ethnicity, and 
education. Model 2 was further adjusted for 
BMI, smoking, cotinine, and menopausal sta-
tus. Model 3 was further adjusted for use of 
vitamin/mineral supplements. Because ignor-
ing diabetes treatment may result in biased 
estimates of the association between selenium 
and glucose or glycosylated hemoglobin, we 
conducted an additional analysis using cen-
sored linear regression (model 4) to correct 
for the effect of medication for diabetes using 
NHANES survey weights (Tobin et al. 2005). 
Tests for linear trend were calculated by includ-
ing serum selenium as a continuous variable in 
the models. To further explore the shape of the 
relationship among serum selenium and plasma 
glucose, glycosylated hemoglobin, and diabetes, 
we used restricted quadratic splines with knots 
at the 5th, 50th, and 95th percentiles of the 
serum selenium distribution. We also evaluated 
the interactions between selenium (modeled as 
quadratic restricted splines) and sex, age, race/
ethnicity, education, BMI, smoking status, or 
use of vitamin/mineral supplements. Statistical 
analyses were performed using weights specific 
for the fasting morning sample in the survey 
package in the R Statistical Software (version 
2.6.1; R Foundation for Statistical Computing, 
Vienna, Austria) to account for the complex 
sampling design and weights. Censored regres-
sion models were estimated using the cnreg 
command in Stata Statistical Software (release 
9.2; StataCorp LP, College Station, TX, USA) 
weighted for NHANES survey weights.
Results
The mean (± SD) serum selenium concen-
tration in the study population was 137.1 ± 
19.9 µg/L. The overall prevalence of diabetes 
was 10.0%. Participants with diabetes were 
more likely to be older, male, and non-His-
panic black or Mexican American and to have 
a higher BMI compared with participants 
without diabetes (Table 1). Serum selenium 
concentrations were positively associated with 
age and with the use of vitamin/mineral sup-
plements, and inversely associated with cur-
rent smoking (Table 2). Men had higher mean 
serum selenium than did women (138.6 vs. 
135.9 µg/L). Non-Hispanic blacks had lower 
mean serum selenium (129.0 µg/L) compared 
Table 1. Characteristics of the study population by diabetes status.
Characteristic Overall Normal Diabetes p-Value
No. 917 796 (90.0%) 121 (10.0%)
Age (years) 54.2 ± 11.3 53.6 ± 11.1 59.4 ± 11.6 0.002
Sex (% female) 53.5 54.6 43.0 0.04
Race (%) 0.09
 Non-Hispanic white 75.8 76.8 66.3
 Non-Hispanic black 10.2 9.8 13.8
 Mexican American 6.1 5.6 10.2
 Other 8.0 7.8 9.7
Education (% high school) 83.8 84.4 77.7 0.11
BMI (kg/m2) 28.6 ± 6.0 28.3 ± 5.9 32.0 ± 6.3 0.002
Smoking (%) 0.69
 Nonsmoker 48.0 48.4 44.9
 Ex-smoker 31.1 30.6 36.1
 Smoker 20.8 21.0 19.1
Dietary supplements (% users) 62.4 62.5 62.0 0.95
Selenium (µg/L) 137.1 ± 19.9 136.4 ± 19.9 143.7 ± 18.3 0.001
Plasma glucose (mg/dL) 102.2 ± 23.9 96.9 ± 9.6 149.9 ± 48.9 —
Glycosylated hemoglobin (%) 5.6 (0.7) 5.4 (0.3) 7.0 (1.4) —
Values are survey-weighted mean ± SD or percentage for continuous or categorical variables, respectively. 
Table 2. Characteristics of the study population by serum selenium quartile (Q).
Quartile of serum selenium
Characteristic
Q1 
(< 124 µg/L)
Q2 
(124–133 µg/L)
Q3 
(134–146 µg/L)
Q4 
(≥ 147 µg/L) p-Trend
No. 208 220 252 237
Age (years) 52.8 54.6 54.5 54.8 0.001
Sex (% female) 61.7 59.7 47.4 47.0 0.07
Race (%)
 Non-Hispanic white 72.1 73.5 74.5 82.6 0.04
 Non-Hispanic black 17.8 10.4 8.3 5.2 0.007
 Mexican American 5.3 5.4 5.3 8.2 0.16
 Other 4.8 10.8 11.9 4.0 0.30
Education (% high school) 80.9 83.3 84.9 85.5 0.37
BMI (kg/m2) 29.2 28.9 28.4 28.1 0.02
Smoking (%)
 Nonsmoker 51.6 47.1 48.2 45.4 0.32
 Ex-smoker 18.0 32.5 32.8 39.8 0.006
 Smoker 30.4 20.4 18.9 14.8 0.005
Dietary supplements 
 (% users)
45.1 58.3 70.4 73.1 0.003
Selenium (µg/L) 115.7 128.6 139.2 161.8 —
Values are survey weighted mean or percentage for continuous or categorical variables, respectively.
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with non-Hispanic whites (138.2 µg/L) and 
with Mexican Americans (140.4 µg/L).
Mean serum selenium concentrations were 
higher in participants with diabetes compared 
with those without it (143.7 vs. 136.4 µg/L, 
p = 0.001). The multivariable adjusted OR 
[95% confidence interval (CI)] for diabe-
tes comparing the highest selenium quartile 
(≥ 147 µg/L) with the lowest (< 124 µg/L) 
was 7.64 (95% CI, 3.34–17.46) (Table 3, 
model 3). In spline regression models, the 
prevalence of diabetes increased with increas-
ing selenium concentrations up to 160 µg/L 
(Figure 1, left). Adjusted ORs for diabetes 
comparing the 80th percentile (150 µg/L) 
with the 20th (122 µg/L) percentile of the 
selenium distribution showed consistent 
findings across clinically relevant subgroups 
(Figure 2).
In multivariable adjusted models, the 
average differences (95% CI) comparing the 
highest with the lowest selenium quartile 
were 9.5 mg/dL (3.4–15.6 mg/dL) for fasting 
plasma glucose, and 0.30% (0.14–0.46%) for 
glycosylated hemoglobin (Table 3, model 3). 
In spline regression models, levels of both 
variables increased with increasing selenium 
concentrations up to 160 µg/L (Figure 1, 
center and right). Extending the definition 
of diabetes to include all participants with 
a previous doctor’s diagnosis of diabetes 
(including nontreated participants) or further 
adjustment for waist circumference and fam-
ily history of diabetes produced similar results 
(data not shown).
Discussion
In this representative cross-sectional study 
of the U.S. population conducted in 
2003–2004, high serum selenium concen-
trations were associated with a higher preva-
lence of diabetes, as well as with higher fasting 
plasma glucose and glycosylated hemoglo-
bin levels. These data are consistent with the 
previous observation of an increased risk of 
diabetes with high selenium concentrations 
in NHANES III, conducted in 1988–1994 
(Bleys et al. 2007). From 1988–1994 to 
2003–2004, however, serum selenium con-
centrations among U.S. subjects ≥ 40 years 
of age increased from 125.8 µg/L (95% CI, 
124.1–127.6 µg/L) in NHANES III (n = 
9,085) to 136.6 µg/L (134.4–138.7 µg/L) 
in NHANES 2003–2004 (n = 2,903). This 
increasing trend in serum selenium levels 
highlights the importance of understanding 
the association between serum selenium lev-
els and diabetes. Moreover, the NPC trial—
a randomized, double-blind clinical trial to 
evaluate the efficacy of selenium supplemen-
tation (200 µg/day) for the prevention of 
cancer—showed an increased risk of diabe-
tes after 7.7 years of follow-up (hazard ratio, 
1.50; 95% CI, 1.03–2.33) comparing sele-
nium supplementation with placebo (Stranges 
et al. 2007). Interestingly, the excess risk of 
Table 3. Adjusted ORs (95% CI) for the presence of diabetes and adjusted differences in fasting glucose and glycosylated hemoglobin comparing the three high-
est quartiles (Q) with the first quartile of serum selenium.
Quartile of serum selenium
Model Q1 (< 124 µg/L) Q2 (124–133 µg/L) Q3 (134–146 µg/L) Q4 (≥ 147 µg/L) p-Trend
Diabetes (%) 3.6 10.0 9.6 16.1
 Model 1 1.00 (Reference) 2.91 (1.15 to 7.33) 2.70 (0.88 to 8.29) 5.24 (2.46 to 11.17) 0.01
 Model 2 1.00 (Reference) 3.14 (1.00 to 9.87) 3.57 (1.25 to 10.17) 7.46 (3.32 to 16.75) 0.002
 Model 3 1.00 (Reference) 3.18 (1.01 to 9.96) 3.65 (1.31 to 10.16) 7.64 (3.34 to 17.46) 0.002
Plasma glucose (mg/dL) 98.6 102.1 101.2 106.5
 Model 1 0.0 (Reference) 3.00 (–0.09 to 6.09) 1.36 (–2.43 to 5.15) 6.98 (0.57 to 13.39) 0.09
 Model 2 0.0 (Reference) 3.43 (–0.12 to 6.98) 2.76 (–0.45 to 5.97) 9.04 (2.75 to 15.33) 0.01
 Model 3 0.0 (Reference) 3.58 (0.05 to 7.12) 3.15 (0.15 to 6.14) 9.46 (3.35 to 15.56) 0.01
 Model 4 0.0 (Reference) 4.17 (–0.39 to 8.73) 3.98 (–0.55 to 8.51) 10.73 (6.17 to 15.28) < 0.001
Glycosylated hemoglobin (%) 5.47 5.55 5.52 5.68
 Model 1 0.0 (Reference) 0.07 (–0.06 to 0.20) 0.05 (–0.04 to 0.14) 0.23 (0.07 to 0.39) 0.06
 Model 2 0.0 (Reference) 0.08 (–0.07 to 0.24) 0.08 (0.00 to 0.16) 0.28 (0.11 to 0.44) 0.01
 Model 3 0.0 (Reference) 0.09 (–0.06 to 0.25) 0.10 (0.02 to 0.17) 0.30 (0.14 to 0.46) 0.007
 Model 4 0.0 (Reference) 0.11 (–0.03 to 0.24) 0.12 (–0.01 to 0.25) 0.33 (0.19 to 0.46) < 0.001
The first row for each outcome shows the unadjusted (survey-weighted) proportions (of diabetes) and averages (of plasma glucose and glycosylated hemoglobin). Models 1–3 used 
multiple linear or logistic regression models with survey weights, strata, and clusters to account for complex survey design. Model 4 used censored regression with survey weights 
only. For results related to the prevalence of diabetes, prevalence ORs are not equivalent to prevalence ratios. To illustrate this difference, the prevalence ratios for diabetes compar-
ing quartiles 2–4 versus the first quartile for model 3, estimated using marginal standardization, were 2.73, 3.05, and 5.32, respectively.
Figure 1. Adjusted ORs (curves) and 95% CIs (gray shading) for diabetes (A) and adjusted differences (and 95% CI) in fasting glucose (B) and glycosylated hemo-
globin (C) by serum selenium concentration. Serum selenium was modeled as restricted quadratic splines with nodes at the 5th, 50th, and 95th percentiles. The 
multivariable linear regression models were adjusted for sex, age, race, education, BMI, smoking, cotinine, postmenopausal status, and use of vitamin and min-
eral supplements (model 3). The odds for diabetes and the values of the continuous variables at the 20th percentile (122 µg/L) of the serum selenium distribution 
were used as reference. The histogram shows the distribution of selenium concentrations in the study population.
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diabetes with selenium supplementation in 
the NPC trial was restricted to participants in 
the highest tertile of plasma selenium at base-
line (> 121.6 µg/L). More recently, SELECT, 
a large randomized clinical trial to evaluate 
the efficacy of selenium supplements (200 µg/
day) on prostate cancer prevention, found 
more cases of diabetes in the group taking 
only selenium compared with placebo (rela-
tive risk, 1.07; 99% CI, 0.94–1.22; p = 0.16) 
but not in the selenium plus vitamin E group 
(relative risk, 0.97; 99% CI, 0.85–1.11; p = 
0.62) (Lippman et al. 2009).
Our findings are consistent with recent 
reports from several U.S. studies of posi-
tive associations of selenium concentrations 
with lipid levels (Bleys et al. 2008b) and with 
hypertension (Laclaustra et al. 2009), as well 
as of U-shaped relationships with cardiovas-
cular end points (Bleys et al. 2008a, 2009; 
Flores-Mateo et al. 2006; Salvini et al. 1995). 
Given the high selenium exposure in the 
United States, the mechanisms underlying 
these associations need to be investigated.
The high soil content of selenium in sev-
eral areas of the United States and the use of 
supplements (Rayman 2008) explain the high 
mean selenium concentration in our sam-
ple (137 µg/L). This level is high compared 
with selenium needs for optimizing seleno-
protein synthesis and activity (Institute of 
Medicine and Panel on Dietary Antioxidants 
and Related Compounds 2000) and rela-
tive to selenium levels in other populations 
(Rayman 2008). Glutathione peroxidases 
synthesis plateaus above serum selenium 
levels of 70–90 µg/L (Combs 2001). Above 
this threshold, serum selenium levels do not 
correlate with glutathione peroxidase activ-
ity or with mRNA synthesis for a variety of 
selenoproteins, but reflect variation in sele-
nomethionine that is incorporated nonspe-
cifically in serum proteins, mainly in albumin 
(Institute of Medicine and Panel on Dietary 
Antioxidants and Related Compounds 2000), 
with unknown physiologic activity. Because 
only one participant in our sample had serum 
selenium levels < 90 µg/L, variability in serum 
selenium levels is unlikely to reflect underly-
ing variation in selenoprotein levels.
Many other countries, including most 
of Europe, have substantially lower serum 
selenium levels (mean values < 100 µg/L) 
(Rayman 2000), mainly due to poorer soil 
content, so our findings may not extrapolate 
to them. In an observational analysis of the 
Supplementation with Antioxidant Vitamins 
and Minerals trial (SU.VI.MAX) conducted 
in France, plasma selenium concentration at 
baseline (mean, 87 µg/L) was positively asso-
ciated with fasting plasma glucose at baseline 
and after 7.5 years of follow-up (Czernichow 
et al. 2006). However, no differences 
in fasting glucose levels were found in the 
randomized component of the trial, compar-
ing a multivitamin supplement that included 
100 µg/day of selenium versus placebo over 
the follow-up (Czernichow et al. 2006). In a 
cross-sectional analysis of the French Etude 
du Viellissement Artérial (EVA), Coudray 
et al. (1997) found no statistically significant 
correlations between plasma selenium (mean, 
87 µg/L) and fasting plasma glucose or diabe-
tes prevalence. Finally, a small cross-sectional 
study of Asian persons residing in Singapore 
also found similar mean serum selenium levels 
among participants with and without diabetes 
(Hughes et al. 1998).
An excess of reactive oxygen species may 
increase insulin resistance and affect pancre-
atic β-cell function (Houstis et al. 2006), and 
some selenium compounds such as selenite 
and methylselenol (a metabolite of selenom-
ethionine) (Rayman 2005) can induce oxi-
dative stress (Drake 2006; Spallholz 1994; 
Spallholz et al. 2004). However, whereas sub-
stantial attention has been paid to explain the 
mechanisms for a potential benefit of increas-
ing serum selenium in low-selenium intake 
populations, the mechanistic explanation 
for the effects of selenium above the levels 
required to maximize glutathione peroxidase 
activity is largely unexplored. Further experi-
mental and epidemiologic research is needed 
to explain the mechanisms underlying the 
observed associations between high selenium 
exposure and cardiometabolic risk factors.
Higher selenium concentrations were 
associated with some diabetes risk factors 
such as increasing age. In contrast, selenium 
concentrations decreased with higher BMI, 
which is one of the stronger diabetes risk 
factors. The associations of selenium and dia-
betes reported were adjusted for these risk 
factors, reducing the possibility that the 
association between selenium and diabetes is 
driven by differences in established diabetes 
risk factors across selenium levels.
The strengths of our study come from the 
rigorous sampling design, the quality of the 
study measurements, and the representative-
ness of the NHANES sample. Among its 
limitations, the cross-sectional design restricts 
our ability to evaluate the temporality of the 
observed association. It is possible that high 
serum selenium levels are related to body 
weight. Nevertheless, the observed associa-
tion persisted after adjusting for BMI as well 
as for use of multivitamin/mineral supple-
ments. The use of a single measurement of 
serum selenium may not reflect completely 
the known high within-person variability 
(Longnecker et al. 1993) and does not pro-
vide information on selenium metabolism. 
A cross-sectional analysis of a subsample of 
the Health Professionals Follow-up Study 
found an inverse association between toenail 
selenium levels and the prevalence of diabetes 
Figure 2. Adjusted ORs (95% CIs) for diabetes comparing the 80th percentile (150 µg/L) with the 20th per-
centile (122 µg/L) of the serum selenium distribution. Serum selenium was modeled as restricted quadratic 
splines with nodes at the 5th, 50th, and 95th percentiles. Multivariable logistic regression models were 
adjusted for sex, age, race, education, BMI, smoking, cotinine, postmenopausal status, and use of vitamin 
and mineral supplements (model 3). The size of the square indicates the number of participants in each 
stratum. p-Values correspond to tests for interaction between selenium splines and selected participant 
characteristics.
Sex (p = 0.32)
 Male 2.30 (0.78–6.79) (n = 435) 
 Female 5.99 (2.41–14.89)  (n = 482) 
Age group (p = 0.09)
 40–60 years 3.40 (0.89–12.98)  (n = 477) 
 > 60 years 2.39 (1.01–5.65)  (n = 440) 
Race (p = 0.35)
 Non-Hispanic white 5.17 (1.68–15.93)  (n = 489) 
 Non-Hispanic black 3.12 (0.58–16.83)  (n = 161) 
 Mexican American 13.98 (3.47–56.32)  (n = 213) 
High school education  ( p = 0.79)
 No 6.04 (1.75–20.90)  (n = 282) 
 Yes 3.05 (1.27–7.35)  (n = 635) 
BMI group (p = 0.81)
 Normal 11.29 (2.14–59.58)  (n = 246) 
 Overweight 4.01 (1.41–11.35)  (n = 369) 
 Obese 2.14 (0.90–5.08)  (n = 302) 
Smoking (p = 0.53)
 Nonsmoker 3.53 (1.38–9.02)  (n = 441) 
 Ex-smoker 4.22 (1.68–10.62)  (n = 299) 
 Smoker 2.00 (0.40–10.09) (n = 177) 
Nutritional supplements ( p = 0.39)
 No 1.94 (0.49–7.65)  (n = 383) 
 Yes 4.60 (1.92–11.01)  (n = 534) 
  
Overall 3.44 (1.73–6.84)  (n = 917) 
Diabetes OR (80th vs. 20th percentile)
0.25 1.00 4.00 16.00 64.00
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(Rajpathak et al. 2005). Serum and toenail 
selenium are both biomarkers of selenium 
intake but are likely to reflect different sele-
nium compartments. Toenail selenium could 
represent a longer trend of selenium intake 
than serum selenium, but there are no data 
supporting the grounds of their differences. 
More detailed analysis of different seleno-
proteins and related activities are needed to 
better understand the association of selenium 
with diabetes.
Conclusions
In summary, high serum selenium concen-
trations were associated with higher preva-
lence of diabetes in a representative survey 
of U.S. adults conducted in 2003–2004. 
These findings are consistent with an earlier 
NHANES survey conducted in 1988–1994. 
Furthermore, these findings are supported by 
randomized evidence from the NPC trial and 
SELECT indicating that selenium supple-
mentation may increase the risk of diabetes 
in selenium-replete populations such as that 
of the United States. High selenium concen-
trations have also been linked to increased 
lipid levels (Bleys et al. 2008b) and hyper-
tension (Laclaustra et al. 2009). Given the 
current diabetes epidemic, the high selenium 
intake from naturally occurring selenium in 
U.S. soil, and the popularity of multivitamin/
mineral supplements containing selenium 
in the United States, these findings call for 
a thorough evaluation of the risks and ben-
efits associated with high selenium status in 
the United States. Furthermore, our findings 
suggest that selenium supplements should 
not be used in the United States until there is 
a better understanding of their potential risks 
and benefits.
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